Westbridge portfolio company APEM Ltd has completed its first acquisition since receiving investment from the private equity firm in March 2019 to support a management buyout.
Deals & Transactions
Relief Therapeutics Holding (Relief), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, has closed a definitive agreement to acquire all outstanding shares of AdVita Lifescience (AdVita), a Germany-based, privately held pharmaceutical company developing effective products and strategies to improve the treatment and diagnosis of rare lung diseases.
Pollen Street Capital and DBAY Advisors have confirmed that the previously-announced recommended offer for Proactis Holdings Plc (Proactis) has been accepted by a majority of shareholders, and as a result the Company has now been acquired by Cafe Bidco Limited and will be de-listed from the AIM sub-market of the London Stock Exchange.
NewQuest Capital Partners (NewQuest), a dedicated secondary private equity platform focused on the Asia-Pacific region, has acquired a minority interest in Kids Clinic India Private Limited, operator of the Cloudnine chain of hospitals across India.
Hedgehog Markets, a decentralised prediction markets platform built on the Solana blockchain, has raised USD3.5 million in a seed funding round.
Galway Sustainable Capital (GSC) has entered into a new, broad-based funding partnership with funds managed by Oaktree Capital Management, (Oaktree).
Equistone Partners Europe (Equistone), one of Europe’s leading mid-market private equity firms, is to sell a majority stake in Bruneau to TowerBrook Capital Partners.
Avedon Capital Partners is to support staffing agency Pro Industry in its ambitious growth path.
Aquila Capital and Axpo, a Swiss renewable energy producer and specialist in wind and solar energy trading, have agreed on a series of power purchase agreements (PPA) and representation services for a solar PV portfolio located in Portugal.
CEVEC Pharmaceuticals (CEVEC), a provider of high-performance cell technology for scalable manufacturing of advanced bio-therapeutics, has closed an internal growth financing round.